SLC5A2 and diabetic kidney disease: This article provides a detailed exploration of SGLT2 inhibitors' impact on DKD, renal outcomes in clinical trials, and the underlying mechanisms of renoprotection.SGLT2 inhibitors' impact on diabetic kidney disease (DKD) The role of SGLT2 inhibitors in DKD management has gained prominence due to their ability to address multiple pathophysiological pathways involved in the progression of renal disease.